Nonacog Alfa
Nonacog Alfa Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Nonacog Alfa is a brand name. Its generic name is Coagulation Factor IX (Recombinant).
Introduction
Nonacog Alfa is a recombinant form of human Factor IX, a protein used to treat clotting disorders including hemophilia B and von Willebrand disease. It is approved by the U.S. Food and Drug Administration (FDA) for the prophylactic and on-demand treatment of hemophilia B. This recombinant factor IX is produced through biotechnology.Uses For
Nonacog Alfa is used to treat or prevent bleeding episodes in individuals with hemophilia B. Hemophilia B is a rare genetic disorder in which the blood does not clot normally due to a missing or deficient form of Factor IX, also known as Christmas Disease.Mechanism of Action
Nonacog Alfa works by aiding in the formation of a blood clot. It helps to activate Factor X, which is then able to convert prothrombin into thrombin, causing the formation of a fibrin clot. This clot is what ultimately prevents or stops a bleeding episode.How Long Does it Take to Work?
The time it takes for Nonacog Alfa to start working varies depending on the specific patient and severity of their clotting disorder. However, in general it usually takes between 5-15 minutes to start working.Absorption
Nonacog Alfa is rapidly absorbed into the bloodstream upon administration.Route of Elimination
Nonacog Alfa is eliminated from the body primarily through the kidneys.Dosage
The dose of Nonacog Alfa will vary depending on the patient's body weight, health condition being treated, and desired therapeutic effect. Generally, it is available in single-use vials and recommended doses range from 25 IU/kg to 100 IU/kg, every 24-72 hours or as needed.Administration
Nonacog Alfa is administered via intravenous (IV) infusion.Side Effect
The most common side effects associated with the use of Nonacog Alfa include: fever, headache, nausea, injection site reactions, hives, and muscle pain.Toxicity
Nonacog Alfa is considered to be of low toxicity. Acute overdose of this medication can lead to thromboembolic events, and may require the administration of anticoagulants.Precaution
Patients should be made aware of the potential risks of Nonacog Alfa prior to administration. This includes the risk of thromboembolic events, anaphylaxis, and the potential for allergic reactions. Patients should also be monitored for signs and symptoms of these complications.Interaction
Nonacog Alfa has the potential to interact with other medications, such as anticoagulants, antifibrinolytics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Patients should be monitored closely for signs and symptoms of any possible drug interactions.Disease Interaction
Nonacog Alfa may interact with certain underlying disease states such as hemophilia, liver disease, and certain immunodeficiency states. Patients should be monitored closely for signs and symptoms of any possible disease interaction.Drug Interaction
Nonacog Alfa has the potential to interact with other drugs. Patients should be monitored closely for signs and symptoms of any possible drug interactions.Food Interactions
Nonacog Alfa does not interact with food.Pregnancy Use
Nonacog Alfa is designated as a pregnancy category C medication, meaning it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.Lactation Use
Nonacog Alfa is not recommended for use by nursing mothers due to the potential for adverse effects in the nursing infant.Acute Overdose
Acute overdose of Nonacog Alfa can lead to increased episodes of bleeding or thromboembolic events. Treatment for an acute overdose typically involves administration of anticoagulants and other supportive measures.Contraindication
Nonacog Alfa is contraindicated in patients who are hypersensitive to this medication or any of its components.Usage Direction
Nonacog Alfa should only be used as directed by a healthcare professional.Storage Condition
Nonacog Alfa should be stored in the refrigerator until ready for use. After administration, any unused or expired product should be discarded.Volume of distribution
The volume of distribution for Nonacog Alfa is approximately 4-8 L/kg.Half-Life
The half-life of Nonacog Alfa is approximately 3 days.Clearance
The clearance of Nonacog Alfa is approximately 0.3 mL/min/kg.Here you find in details version of Nonacog Alfa
Some Frequently Asked Questions About Nonacog Alfa
https://www.medicinesfaq.com/brand/nonacog-alfa,
http://www.uniprot.org/uniprot/P00740,
https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=K02402,
http://www.genome.jp/dbget-bin/www_bget?cpd:C03101,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508858,
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1300488,
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000964,
http://www.pharmgkb.org/drug/PA164744952,
http://www.rxlist.com/cgi/generic2/factorix.htm,
https://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,
https://en.wikipedia.org/wiki/Factor_IX,